Phase III KEYNOTE-590 study of chemotherapy plus pembrolizumab versus chemotherapy plus placebo as first-line therapy for patients (Pts) with advanced esophageal or esophagogastric junction (E/EGJ) cancer


Kato K., Shah M. A. , Enzinger P. C. , Bennouna J., Shen L., Adenis A., ...More

43rd ESMO Congress (ESMO), Munich, Germany, 19 - 23 October 2018, vol.29 identifier

  • Publication Type: Conference Paper / Summary Text
  • Volume: 29
  • City: Munich
  • Country: Germany